Fetal left ventricular myocardial performance index measured at 11-14 weeks of gestation in fetuses with an increased nuchal translucency.


Journal

The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 31 07 2022
accepted: 30 12 2022
medline: 4 4 2023
pubmed: 25 1 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

This study aimed to evaluate the effect of an increase in nuchal translucency (NT) thickness on the myocardial performance index (MPI) in fetuses without cardiac anomaly in the first trimester and to determine whether a difference in MPI between those with and without trisomy 21 in these fetuses could be determined. The study group consisted of 53 pregnancies complicated with increased NT thickness without any associated structural anomalies. Forty-six gestational age-matched pregnant women whose fetuses had normal NT thickness were enrolled as the control group. In the increased NT thickness group, the mean isovolumetric relaxation time (IRT) value (0.050 ± 0.011 s) was significantly higher and the mean ejection time (ET) value (0.149 ± 0.010 s) was significantly lower than those values in the normal NT thickness group (0.045 ± 0.005 and 0.155 ± 0.009 s, p = 0.023 and p = 0.009, respectively). We found a significantly higher mean left MPI value in the increased NT thickness group (0.574 ± 0.153) versus the normal NT thickness group (0.487 ± 0.107, p < 0.001). Within the increased NT thickness group, the mean left MPI value was similar in the fetuses with normal karyotype and those with trisomy 21 (p = 0.419). We demonstrated a significantly greater mean MPI value in the increased NT thickness group than in the normal NT thickness group. Within the increased NT thickness group, no differences in the left MPI value in the fetuses with normal karyotype and the fetuses with trisomy 21 were found.

Identifiants

pubmed: 36691372
doi: 10.1111/jog.15551
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1121-1128

Informations de copyright

© 2023 Japan Society of Obstetrics and Gynecology.

Références

Salman GS. The associations of nuchal translucency and fetal abnormalities; significance and implications. J Clin Diagn Res. 2013;7:936-41.
Ji X, Xia Y, Zhang H, Wang H, Shi R, Han Z. Study on the application of ultrasonography in the diagnosis of fetal cardiac structural abnormalities and the relationship between fetal cardiac structural abnormalities with chromosome abnormalities in early pregnancy. Ann Transl Med. 2021;9:1790.
Gedik Özköse Z, Oğlak SC, Behram M, Ölmez F, Süzen Çaypınar S, Bestel A, et al. Retrospective analysis of prenatal invasive diagnostic procedures in a tertiary center. Aegean J Obstet Gynecol. 2021;3:1-5.
De Domenico R, Faraci M, Hyseni E, Di Prima FA, Valenti O, Monte S, et al. Increased nuchal traslucency in normal karyotype fetuses. J Prenat Med. 2011;5:23-6.
Stuurman KE, van der Mespel-Brouwer MH, Engels MAJ, Elting MW, Bhola SL, Meijers-Heijboer H. Isolated increased nuchal translucency in first trimester ultrasound scan: diagnostic yield of prenatal microarray and outcome of pregnancy. Front Med (Lausanne). 2021;8:737936.
Oğlak SC, Bademkıran MH, Obut M. Predictor variables in the success of slow-release dinoprostone used for cervical ripening in intrauterine growth restriction pregnancies. J Gynecol Obstet Hum Reprod. 2020;49:101739.
Nafziger E, Vilensky JA. The anatomy of nuchal translucency at 10-14 weeks gestation in fetuses with trisomy 21: an incredible medical mystery. Clin Anat. 2014;27:353-9.
Mula R, Grande M, Bennasar M, Crispi F, Borobio V, Martinez JM, et al. Further insights into diastolic dysfunction in first-trimester trisomy-21 fetuses. Ultrasound Obstet Gynecol. 2015;45:205-10.
Crispi F, Gratacós E. Fetal cardiac function: technical considerations and potential research and clinical applications. Fetal Diagn Ther. 2012;32:47-64.
Russell NE, McAuliffe FM. First-trimester fetal cardiac function. J Ultrasound Med. 2008;27:379-83.
Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995;26:135-6.
Cruz-Martínez R, Figueras F, Bennasar M, García-Posadas R, Crispi F, Hernández-Andrade E, et al. Normal reference ranges from 11 to 41 weeks' gestation of fetal left modified myocardial performance index by conventional Doppler with the use of stringent criteria for delimitation of the time periods. Fetal Diagn Ther. 2012;32:79-86.
Luewan S, Tongprasert F, Srisupundit K, Traisrisilp K, Tongsong T. Reference ranges of myocardial performance index from 12 to 40 weeks of gestation. Arch Gynecol Obstet. 2014;290:859-65.
Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 2005;192:1005-21.
Salvesen K, Abramowicz J, Ter Haar G, Miloro P, Sinkovskaya E, Dall'Asta A, et al. ISUOG statement on the safe use of doppler for fetal ultrasound examination in the first 13 + 6 weeks of pregnancy (updated). Ultrasound Obstet Gynecol. 2021;57:1020.
Friedman D, Buyon J, Kim M, Glickstein JS. Fetal cardiac function assessed by Doppler myocardial performance index (Tei index). Ultrasound Obstet Gynecol. 2003;21:33-6.
Fujita Y, Athayde N, Tokunaga S, Trudinger B. Measurement of cardiac contractility using fetal isovolumetric contraction time in fetal tachyarrhythmia. Ultrasound Med Biol. 2011;37:184-8.
Öcal DF, Yakut K, Öztürk FH, Öztürk M, Oğuz Y, Altınboğa O, et al. Utility of the modified myocardial performance index in growth-restricted fetuses. Echocardiography. 2019;36:1895-900.
Alhakak AS, Teerlink JR, Lindenfeld J, Böhm M, Rosano GMC, Biering-Sørensen T. The significance of left ventricular ejection time in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23:541-51.
Clur SA, Mathijssen IB, Pajkrt E, Cook A, Laurini RN, Ottenkamp J, et al. Structural heart defects associated with an increased nuchal translucency: 9 years experience in a referral centre. Prenat Diagn. 2008;28:347-54.
Sinajon P, Chitayat D, Roifman M, Wasim S, Carmona S, Ryan G, et al. Microarray and RASopathy-disorder testing in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol. 2020;55:383-90.
Mula R, Goncé A, Bennásar M, Arigita M, Meler E, Nadal A, et al. Increased nuchal translucency and normal karyotype: perinatal and pediatric outcomes at 2 years of age. Ultrasound Obstet Gynecol. 2012;39:34-41.
Huggon IC, Turan O, Allan LD. Doppler assessment of cardiac function at 11-14 weeks' gestation in fetuses with normal and increased nuchal translucency. Ultrasound Obstet Gynecol. 2004;24:390-8.
Yakut K, Öcal DF, Öztürk F, Öztürk M, Sanhal CY, Çelen Ş, et al. Turkish reference ranges for the left fetal modified myocardial performance index. Turk J Pediatr. 2021;63:1038-47.
Cruz-Martinez R, Figueras F, Jaramillo JJ, Meler E, Méndez A, Hernandez-Andrade E, et al. Learning curve for Doppler measurement of fetal modified myocardial performance index. Ultrasound Obstet Gynecol. 2011;37:158-62.
Clur SA, Oude Rengerink K, Mol BW, Ottenkamp J, Bilardo CM. Fetal cardiac function between 11 and 35 weeks' gestation and nuchal translucency thickness. Ultrasound Obstet Gynecol. 2011;37:48-56.
Clur SA, Oude Rengerink K, Ottenkamp J, Bilardo CM. Cardiac function in trisomy 21 fetuses. Ultrasound Obstet Gynecol. 2011;37:163-71.
Leung V, Avnet H, Henry A, Wang J, Redmond S, Welsh AW. Automation of the fetal right myocardial performance index to optimise repeatability. Fetal Diagn Ther. 2018;44:28-35.
Hernandez-Andrade E, López-Tenorio J, Figueroa-Diesel H, Sanin-Blair J, Carreras E, Cabero L, et al. A modified myocardial performance (Tei) index based on the use of valve clicks improves reproducibility of fetal left cardiac function assessment. Ultrasound Obstet Gynecol. 2005;26:227-32.

Auteurs

Salim Sezer (S)

Department of Perinatology, Esenyurt University Hospital, Istanbul, Turkey.

Süleyman Cemil Oğlak (SC)

Department of Obstetrics and Gynecology, Health Sciences University, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey.

Başak Kaya (B)

Department of Perinatology, Medipol University Hospital, Istanbul, Turkey.

Mustafa Behram (M)

Department of Perinatology, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

Zeynep Gedik Özköse (Z)

Department of Perinatology, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

Sema Süzen Çaypınar (S)

Department of Perinatology, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

Züat Acar (Z)

Department of Perinatology, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

Alper Gezdirici (A)

Department of Medical Genetics, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.

Helen Bornaun (H)

Department of Pediatric Cardiology, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH